Success Story: NIW Approved for Hematology Researcher Advancing Real-World Treatment Strategies for Hematologic Cancers
Client’s Testimonial:
"Thank you so much for all your help. I am extremely satisfied with your services and your professional, meticulous approach.”
On June 15th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Resident Physician in the Field of Hematology (Approval Notice).
General Field: Hematology
Position at the Time of Case Filing: Resident Physician
Country of Origin: Pakistan
State of Residence at the Time of Filing: Florida
Approval Notice Date: June 15th, 2026
Processing Time: 7 months, 23 days (Premium Processing Upgrade Requested)
Case Summary:
We are pleased to share the approval of an I-140 National Interest Waiver petition for a hematology researcher whose work addresses major challenges in hematologic cancer care. The client earned an M.B.B.S. degree and proposed to continue clinical, pathological, and molecular research to characterize myeloid and lymphoma malignancy phenotypes. Her goal is to identify prognostic indicators and treatment strategies that can support evidence-based clinical guidelines and improve real-world care for patients with hematologic cancers.
The client is a resident physician with an active research focus in hematology. In the petition, we emphasized that this endeavor had substantial merit and national importance because hematologic cancers remain a serious public health challenge, and more precise prognostic tools are needed to improve survival prediction, treatment selection, and clinical decision-making.
Connecting Hematology Research to Cancer Treatment Innovation
A key strength of the case was that the client’s work was not framed as clinical research alone. Instead, the petition showed how her research could improve risk stratification and treatment planning for patients with complex blood cancers. Her planned work included studying bone marrow transplantation outcomes, rare and aggressive lymphoma conditions, and second-line treatment outcomes for relapsed or refractory hematologic cancers.
Research Impact and Professional Recognition
In support of the petition, we documented:
- 9 peer-reviewed journal articles, including 2 first-authored papers
- 6 conference abstracts, including 2 first-authored abstracts
- 49 citations to the client’s published work
These metrics were not presented as self-sufficient. Instead, we showed how they reflected research influence and independent reliance. Other researchers had relied on the client’s findings to advance studies in acute myeloid leukemia, chronic myelomonocytic leukemia, survival prediction, treatment response, and transplant-related decision-making.
Approval and Outcome
By connecting the client’s medical training, resident physician role, publication record, citation history, independent research influence, and future research plan into one coherent narrative, we demonstrated that the client was well-positioned to advance an endeavor of clear national importance. We are proud to have supported this client in achieving I-140 NIW approval and look forward to her continued contributions to hematology, prognostic modeling, evidence-based clinical guidelines, and improved treatment strategies in the United States.